Prevalence, clinical characteristics, and biological markers of postmenopausal osteoporosis and knee osteoarthritis in Beijing: study protocol for a cross-sectional and prospective study.
Zhenkai Lu, Wenye Feng, Yaxing Wang, Xuming Zhang, Xu Wei, Ming Chen, Shangquan Wang, Ting Cheng, Xin Cui, Yanming Xie
{"title":"Prevalence, clinical characteristics, and biological markers of postmenopausal osteoporosis and knee osteoarthritis in Beijing: study protocol for a cross-sectional and prospective study.","authors":"Zhenkai Lu, Wenye Feng, Yaxing Wang, Xuming Zhang, Xu Wei, Ming Chen, Shangquan Wang, Ting Cheng, Xin Cui, Yanming Xie","doi":"10.3389/fmed.2025.1582533","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Postmenopausal osteoporosis (PMOP) and knee osteoarthritis (KOA) are common musculoskeletal disorders that share risk factors such as aging, hormonal changes, and inflammation. PMOP often remains asymptomatic until fractures occur, while KOA leads to pain and disability. Their comorbidity remains underexplored, particularly in community settings. This study aims to investigate the prevalence, risk factors, and clinical features of PMOP-KOA comorbidity among Beijing residents aged 45-80 years, providing evidence-based recommendations for early identification, prevention, and management.</p><p><strong>Methods: </strong>Over 2 years, this study will conduct a PMOP-KOA screening and prospective follow-up in the Beijing community to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA. This study will undertake bone mineral density detection, collect biological samples, and record information via questionnaires.</p><p><strong>Discussion: </strong>The study aims to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA comorbidity and explore related traditional Chinese medicine syndromes based on large community-based samples in Beijing. Data on PMOP-KOA occurrence and associated risk factors over the 2 years follow-up will be available on the Chinese Clinical Trial Registry (ChiCTR2300073575).</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1582533"},"PeriodicalIF":3.1000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174043/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1582533","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Postmenopausal osteoporosis (PMOP) and knee osteoarthritis (KOA) are common musculoskeletal disorders that share risk factors such as aging, hormonal changes, and inflammation. PMOP often remains asymptomatic until fractures occur, while KOA leads to pain and disability. Their comorbidity remains underexplored, particularly in community settings. This study aims to investigate the prevalence, risk factors, and clinical features of PMOP-KOA comorbidity among Beijing residents aged 45-80 years, providing evidence-based recommendations for early identification, prevention, and management.
Methods: Over 2 years, this study will conduct a PMOP-KOA screening and prospective follow-up in the Beijing community to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA. This study will undertake bone mineral density detection, collect biological samples, and record information via questionnaires.
Discussion: The study aims to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA comorbidity and explore related traditional Chinese medicine syndromes based on large community-based samples in Beijing. Data on PMOP-KOA occurrence and associated risk factors over the 2 years follow-up will be available on the Chinese Clinical Trial Registry (ChiCTR2300073575).
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
